Share Price and Basic Stock Data
Last Updated: January 24, 2026, 5:35 pm
| PEG Ratio | 1.28 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Epigral Ltd operates in the agrochemical and pesticide industry and has shown significant growth in its revenue streams. For the fiscal year ending March 2025, the company reported sales of ₹2,550 Cr, marking an increase from ₹1,929 Cr in March 2024 and ₹2,188 Cr in March 2023. This upward trend reflects a robust compound annual growth rate, particularly when compared to historical figures such as ₹1,551 Cr in March 2022. Quarterly sales also illustrate volatility, with a recent high of ₹651 Cr in June 2024, followed by a slight decline to ₹626 Cr in September 2024. Such fluctuations are common in the sector, affected by seasonal demand and market conditions. The company’s total sales for the trailing twelve months stood at ₹2,467 Cr, indicating strong operational performance. Overall, Epigral Ltd’s ability to maintain revenue growth amidst industry challenges positions it favorably within the agrochemical sector.
Profitability and Efficiency Metrics
Epigral Ltd’s profitability metrics indicate strong operational efficiency. The company achieved a net profit of ₹357 Cr for the fiscal year ending March 2025, an increase from ₹196 Cr in March 2024 and ₹353 Cr in March 2023. The net profit margin improved to 13.98%, up from 10.15% in March 2024, showcasing effective cost management strategies. The operating profit margin (OPM) for the same period stood at 28.46%, reflecting consistent operational efficiency, though it has fluctuated from a high of 38% in March 2016 to a more stabilized range in recent years. Furthermore, the interest coverage ratio (ICR) was reported at 13.63x, indicating a strong ability to meet interest obligations, which is significantly higher than typical sector averages. These metrics highlight Epigral Ltd’s capacity to generate profit relative to its sales and operational costs, positioning the company as a competitive player in the agrochemical market.
Balance Sheet Strength and Financial Ratios
Epigral Ltd’s balance sheet reflects a solid financial foundation, with total assets reported at ₹3,151 Cr and total liabilities at ₹2,794 Cr for March 2025. The company’s reserves reached ₹2,057 Cr, illustrating a strong equity position, while borrowings were recorded at ₹537 Cr, resulting in a low debt-to-equity ratio of 0.30x. This indicates prudent financial management and a conservative approach towards leveraging. The return on equity (ROE) stood at 22.3%, which is favorable compared to industry benchmarks, signaling efficient use of shareholder funds. Additionally, the company’s current ratio of 1.57x suggests adequate liquidity to cover short-term obligations. However, the inventory turnover ratio of 7.83x indicates efficient inventory management, though a closer look at the cash conversion cycle of 88 days will be essential in assessing operational efficiency. Overall, the balance sheet metrics portray Epigral Ltd as a financially healthy entity with a balanced approach to growth and risk management.
Shareholding Pattern and Investor Confidence
As of September 2025, Epigral Ltd’s shareholding pattern reveals a dominant promoter holding of 68.83%, indicating strong management control and alignment with shareholder interests. Institutional investors hold a modest stake, with foreign institutional investors (FIIs) at 2.71% and domestic institutional investors (DIIs) at 4.93%. This suggests a cautious institutional interest, which may reflect concerns about market volatility or sector-specific risks. The public shareholding stands at 23.52%, with the number of shareholders decreasing to 78,605 from previous periods, indicating potential consolidation in investor interest. The gradual decline in promoter shareholding from 71.21% in December 2022 to 68.83% may raise questions about long-term commitment, but it also reflects a strategic move to enhance liquidity. Overall, while the promoter’s substantial stake provides stability, the low institutional participation may limit broader market confidence.
Outlook, Risks, and Final Insight
The outlook for Epigral Ltd appears optimistic, supported by strong revenue growth and profitability metrics. However, the company faces several risks, including fluctuating commodity prices, which can impact margins, and potential regulatory changes that affect the agrochemical sector. Additionally, the decline in institutional investor interest could signal caution among larger market players regarding the company’s future prospects. Should Epigral Ltd continue to leverage its operational efficiencies and manage costs effectively, it could sustain its growth trajectory. Conversely, any adverse market conditions or failure to adapt to regulatory changes could hinder performance. The company’s focus on innovation and maintaining strong relationships with stakeholders will be critical in navigating these challenges and maximizing shareholder value in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 4,597 Cr. | 1,066 | 2,114/1,056 | 11.4 | 487 | 0.56 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 769 Cr. | 228 | 391/165 | 15.8 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 58.3 Cr. | 112 | 149/56.6 | 10.4 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,653 Cr. | 205 | 331/198 | 100 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 787 Cr. | 22.2 | 36.9/16.3 | 61.5 | 22.8 | 0.90 % | 12.9 % | 9.95 % | 1.00 |
| Industry Average | 10,301.05 Cr | 1,038.40 | 28.96 | 369.04 | 0.46% | 15.21% | 19.87% | 6.67 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 556 | 538 | 562 | 455 | 478 | 472 | 525 | 651 | 626 | 645 | 628 | 607 | 587 |
| Expenses | 375 | 371 | 407 | 360 | 370 | 349 | 369 | 475 | 448 | 463 | 454 | 443 | 455 |
| Operating Profit | 180 | 167 | 155 | 95 | 108 | 123 | 155 | 176 | 178 | 183 | 173 | 163 | 132 |
| OPM % | 32% | 31% | 28% | 21% | 23% | 26% | 30% | 27% | 28% | 28% | 28% | 27% | 23% |
| Other Income | 2 | -0 | 5 | 2 | 1 | 2 | 2 | 2 | 6 | 4 | 3 | 8 | 2 |
| Interest | 14 | 21 | 19 | 18 | 21 | 20 | 14 | 14 | 27 | -0 | 12 | 23 | 22 |
| Depreciation | 26 | 31 | 30 | 31 | 32 | 31 | 30 | 33 | 32 | 33 | 34 | 42 | 42 |
| Profit before tax | 142 | 114 | 110 | 48 | 56 | 74 | 113 | 131 | 124 | 154 | 131 | 107 | 70 |
| Tax % | 35% | 33% | 30% | 33% | 32% | 34% | 32% | 34% | 35% | 33% | 34% | -50% | 26% |
| Net Profit | 92 | 77 | 77 | 32 | 38 | 49 | 77 | 86 | 81 | 104 | 87 | 160 | 52 |
| EPS in Rs | 22.04 | 18.58 | 18.48 | 7.62 | 9.18 | 11.87 | 18.45 | 20.70 | 19.38 | 24.00 | 20.08 | 37.18 | 11.94 |
Last Updated: December 27, 2025, 2:06 am
Below is a detailed analysis of the quarterly data for Epigral Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 587.00 Cr.. The value appears to be declining and may need further review. It has decreased from 607.00 Cr. (Jun 2025) to 587.00 Cr., marking a decrease of 20.00 Cr..
- For Expenses, as of Sep 2025, the value is 455.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 443.00 Cr. (Jun 2025) to 455.00 Cr., marking an increase of 12.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 132.00 Cr.. The value appears to be declining and may need further review. It has decreased from 163.00 Cr. (Jun 2025) to 132.00 Cr., marking a decrease of 31.00 Cr..
- For OPM %, as of Sep 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Jun 2025) to 23.00%, marking a decrease of 4.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 23.00 Cr. (Jun 2025) to 22.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 42.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 42.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 70.00 Cr.. The value appears to be declining and may need further review. It has decreased from 107.00 Cr. (Jun 2025) to 70.00 Cr., marking a decrease of 37.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from -50.00% (Jun 2025) to 26.00%, marking an increase of 76.00%.
- For Net Profit, as of Sep 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 160.00 Cr. (Jun 2025) to 52.00 Cr., marking a decrease of 108.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 11.94. The value appears to be declining and may need further review. It has decreased from 37.18 (Jun 2025) to 11.94, marking a decrease of 25.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:46 am
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 394 | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,467 |
| Expenses | 245 | 248 | 346 | 405 | 416 | 567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,815 |
| Operating Profit | 149 | 144 | 252 | 306 | 194 | 261 | 510 | 689 | 481 | 711 | 652 |
| OPM % | 38% | 37% | 42% | 43% | 32% | 32% | 33% | 31% | 25% | 28% | 26% |
| Other Income | 2 | 1 | 8 | 16 | 2 | 2 | 4 | 8 | 6 | 15 | 17 |
| Interest | 19 | 14 | 9 | 25 | 11 | 29 | 44 | 66 | 73 | 53 | 57 |
| Depreciation | 44 | 55 | 55 | 54 | 44 | 74 | 86 | 109 | 124 | 133 | 151 |
| Profit before tax | 88 | 75 | 195 | 242 | 141 | 161 | 383 | 523 | 291 | 540 | 461 |
| Tax % | 23% | 11% | 20% | 25% | 21% | 37% | 34% | 32% | 33% | 34% | |
| Net Profit | 67 | 67 | 155 | 183 | 112 | 101 | 253 | 353 | 196 | 357 | 402 |
| EPS in Rs | 9.49 | 9.40 | 21.97 | 44.38 | 27.19 | 24.48 | 60.84 | 85.04 | 47.12 | 82.68 | 93.20 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6% | 11% | 7% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 131.34% | 18.06% | -38.80% | -9.82% | 150.50% | 39.53% | -44.48% | 82.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | 131.34% | -113.28% | -56.86% | 28.98% | 160.32% | -110.97% | -84.00% | 126.62% |
Epigral Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 18% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 12% |
| TTM: | 72% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 7% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 25% |
| Last Year: | 22% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: January 7, 2026, 5:25 pm
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 71 | 71 | 71 | 41 | 42 | 42 | 42 | 42 | 42 | 43 | 43 |
| Reserves | 224 | 291 | 447 | 241 | 331 | 432 | 684 | 1,028 | 1,213 | 1,860 | 2,057 |
| Borrowings | 190 | 123 | 74 | 601 | 737 | 753 | 993 | 879 | 964 | 593 | 537 |
| Other Liabilities | 55 | 42 | 79 | 162 | 164 | 223 | 405 | 484 | 576 | 655 | 598 |
| Total Liabilities | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 | 3,235 |
| Fixed Assets | 364 | 398 | 347 | 295 | 440 | 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | 2,176 |
| CWIP | 69 | 3 | 79 | 468 | 691 | 126 | 589 | 158 | 483 | 64 | 309 |
| Investments | 0 | 29 | 71 | 0 | 0 | 0 | 0 | 21 | 21 | 97 | 44 |
| Other Assets | 106 | 98 | 173 | 281 | 142 | 221 | 467 | 449 | 524 | 752 | 707 |
| Total Assets | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 | 3,235 |
Below is a detailed analysis of the balance sheet data for Epigral Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 43.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 43.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,057.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,860.00 Cr. (Mar 2025) to 2,057.00 Cr., marking an increase of 197.00 Cr..
- For Borrowings, as of Sep 2025, the value is 537.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 593.00 Cr. (Mar 2025) to 537.00 Cr., marking a decrease of 56.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 598.00 Cr.. The value appears to be improving (decreasing). It has decreased from 655.00 Cr. (Mar 2025) to 598.00 Cr., marking a decrease of 57.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,235.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,151.00 Cr. (Mar 2025) to 3,235.00 Cr., marking an increase of 84.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,176.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,238.00 Cr. (Mar 2025) to 2,176.00 Cr., marking a decrease of 62.00 Cr..
- For CWIP, as of Sep 2025, the value is 309.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 309.00 Cr., marking an increase of 245.00 Cr..
- For Investments, as of Sep 2025, the value is 44.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 44.00 Cr., marking a decrease of 53.00 Cr..
- For Other Assets, as of Sep 2025, the value is 707.00 Cr.. The value appears to be declining and may need further review. It has decreased from 752.00 Cr. (Mar 2025) to 707.00 Cr., marking a decrease of 45.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,235.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,151.00 Cr. (Mar 2025) to 3,235.00 Cr., marking an increase of 84.00 Cr..
Notably, the Reserves (2,057.00 Cr.) exceed the Borrowings (537.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -41.00 | 21.00 | 178.00 | -295.00 | -543.00 | -492.00 | -483.00 | -190.00 | -483.00 | 118.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 41 | 47 | 40 | 46 | 52 | 60 | 28 | 34 | 33 |
| Inventory Days | 75 | 59 | 45 | 58 | 64 | 51 | 74 | 69 | 90 | 105 |
| Days Payable | 31 | 37 | 51 | 52 | 62 | 69 | 42 | 36 | 63 | 50 |
| Cash Conversion Cycle | 86 | 63 | 42 | 46 | 48 | 34 | 92 | 61 | 61 | 88 |
| Working Capital Days | 43 | 40 | 19 | -27 | -76 | -92 | -26 | -41 | -54 | 26 |
| ROCE % | 18% | 37% | 36% | 15% | 16% | 29% | 32% | 17% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Bandhan Small Cap Fund | 690,108 | 0.44 | 84.2 | 459,048 | 2026-01-26 05:46:41 | 50.33% |
| HSBC Value Fund | 494,874 | 0.41 | 60.38 | N/A | N/A | N/A |
| HSBC Focused Fund | 250,650 | 1.78 | 30.58 | N/A | N/A | N/A |
| HSBC Multi Cap Fund | 237,996 | 0.55 | 29.04 | N/A | N/A | N/A |
| HSBC ELSS Tax saver Fund | 121,645 | 0.36 | 14.84 | N/A | N/A | N/A |
| Bandhan Business Cycle Fund | 91,662 | 0.77 | 11.18 | N/A | N/A | N/A |
| HSBC Flexi Cap Fund | 80,365 | 0.19 | 9.81 | 213,965 | 2026-01-26 05:46:41 | -62.44% |
| HSBC India Export Opportunities Fund | 76,533 | 0.66 | 9.34 | N/A | N/A | N/A |
| HSBC Business Cycles Fund | 76,350 | 0.82 | 9.32 | N/A | N/A | N/A |
| HSBC Tax Saver Equity Fund | 17,300 | 0.87 | 2.11 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 84.68 | 47.14 | 85.03 | 60.84 | 24.27 |
| Diluted EPS (Rs.) | 84.68 | 47.14 | 85.03 | 60.84 | 24.27 |
| Cash EPS (Rs.) | 113.41 | 76.87 | 111.25 | 81.51 | 41.97 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 441.48 | 301.83 | 257.30 | 174.72 | 113.88 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 441.48 | 301.83 | 257.30 | 174.72 | 113.88 |
| Revenue From Operations / Share (Rs.) | 591.13 | 464.30 | 526.69 | 373.27 | 199.41 |
| PBDIT / Share (Rs.) | 168.27 | 117.39 | 167.73 | 123.61 | 63.42 |
| PBIT / Share (Rs.) | 137.54 | 87.66 | 141.51 | 102.93 | 45.72 |
| PBT / Share (Rs.) | 125.20 | 69.97 | 125.75 | 92.28 | 38.71 |
| Net Profit / Share (Rs.) | 82.68 | 47.13 | 85.03 | 60.84 | 24.27 |
| NP After MI And SOA / Share (Rs.) | 82.91 | 47.14 | 85.03 | 60.84 | 24.27 |
| PBDIT Margin (%) | 28.46 | 25.28 | 31.84 | 33.11 | 31.80 |
| PBIT Margin (%) | 23.26 | 18.87 | 26.86 | 27.57 | 22.92 |
| PBT Margin (%) | 21.17 | 15.06 | 23.87 | 24.72 | 19.41 |
| Net Profit Margin (%) | 13.98 | 10.15 | 16.14 | 16.29 | 12.16 |
| NP After MI And SOA Margin (%) | 14.02 | 10.15 | 16.14 | 16.29 | 12.16 |
| Return on Networth / Equity (%) | 18.78 | 15.61 | 33.04 | 34.82 | 21.30 |
| Return on Capital Employeed (%) | 22.30 | 18.07 | 32.94 | 26.87 | 17.92 |
| Return On Assets (%) | 11.34 | 7.00 | 14.52 | 11.90 | 6.96 |
| Long Term Debt / Equity (X) | 0.23 | 0.39 | 0.40 | 1.06 | 0.71 |
| Total Debt / Equity (X) | 0.30 | 0.72 | 0.71 | 1.36 | 0.87 |
| Asset Turnover Ratio (%) | 0.85 | 0.73 | 0.96 | 0.86 | 0.00 |
| Current Ratio (X) | 1.57 | 0.64 | 0.64 | 0.83 | 0.46 |
| Quick Ratio (X) | 0.78 | 0.30 | 0.32 | 0.55 | 0.32 |
| Inventory Turnover Ratio (X) | 7.83 | 4.51 | 6.62 | 7.30 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 8.82 | 5.30 | 2.94 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.43 | 3.25 | 2.24 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 91.18 | 94.70 | 97.06 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.57 | 96.75 | 97.76 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 13.63 | 6.64 | 10.64 | 11.60 | 9.05 |
| Interest Coverage Ratio (Post Tax) (X) | 7.70 | 3.66 | 6.39 | 6.71 | 4.46 |
| Enterprise Value (Cr.) | 8753.81 | 5509.59 | 4780.47 | 5010.23 | 0.00 |
| EV / Net Operating Revenue (X) | 3.43 | 2.86 | 2.18 | 3.23 | 0.00 |
| EV / EBITDA (X) | 12.06 | 11.30 | 6.86 | 9.76 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 3.21 | 2.36 | 1.79 | 2.61 | 0.00 |
| Retention Ratios (%) | 91.17 | 94.69 | 97.05 | 0.00 | 0.00 |
| Price / BV (X) | 4.30 | 3.63 | 3.67 | 5.57 | 0.00 |
| Price / Net Operating Revenue (X) | 3.21 | 2.36 | 1.79 | 2.61 | 0.00 |
| EarningsYield | 0.04 | 0.04 | 0.09 | 0.06 | 0.00 |
After reviewing the key financial ratios for Epigral Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
- For Diluted EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
- For Cash EPS (Rs.), as of Mar 25, the value is 113.41. This value is within the healthy range. It has increased from 76.87 (Mar 24) to 113.41, marking an increase of 36.54.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 591.13. It has increased from 464.30 (Mar 24) to 591.13, marking an increase of 126.83.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 168.27. This value is within the healthy range. It has increased from 117.39 (Mar 24) to 168.27, marking an increase of 50.88.
- For PBIT / Share (Rs.), as of Mar 25, the value is 137.54. This value is within the healthy range. It has increased from 87.66 (Mar 24) to 137.54, marking an increase of 49.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 125.20. This value is within the healthy range. It has increased from 69.97 (Mar 24) to 125.20, marking an increase of 55.23.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 82.68. This value is within the healthy range. It has increased from 47.13 (Mar 24) to 82.68, marking an increase of 35.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 82.91. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 82.91, marking an increase of 35.77.
- For PBDIT Margin (%), as of Mar 25, the value is 28.46. This value is within the healthy range. It has increased from 25.28 (Mar 24) to 28.46, marking an increase of 3.18.
- For PBIT Margin (%), as of Mar 25, the value is 23.26. This value exceeds the healthy maximum of 20. It has increased from 18.87 (Mar 24) to 23.26, marking an increase of 4.39.
- For PBT Margin (%), as of Mar 25, the value is 21.17. This value is within the healthy range. It has increased from 15.06 (Mar 24) to 21.17, marking an increase of 6.11.
- For Net Profit Margin (%), as of Mar 25, the value is 13.98. This value exceeds the healthy maximum of 10. It has increased from 10.15 (Mar 24) to 13.98, marking an increase of 3.83.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.02. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 14.02, marking an increase of 3.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has increased from 15.61 (Mar 24) to 18.78, marking an increase of 3.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.30. This value is within the healthy range. It has increased from 18.07 (Mar 24) to 22.30, marking an increase of 4.23.
- For Return On Assets (%), as of Mar 25, the value is 11.34. This value is within the healthy range. It has increased from 7.00 (Mar 24) to 11.34, marking an increase of 4.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.23, marking a decrease of 0.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.72 (Mar 24) to 0.30, marking a decrease of 0.42.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has increased from 0.73 (Mar 24) to 0.85, marking an increase of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 1.57. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 1.57, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has increased from 0.30 (Mar 24) to 0.78, marking an increase of 0.48.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 4.51 (Mar 24) to 7.83, marking an increase of 3.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.82. This value is below the healthy minimum of 20. It has increased from 5.30 (Mar 24) to 8.82, marking an increase of 3.52.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 20. It has increased from 3.25 (Mar 24) to 6.43, marking an increase of 3.18.
- For Earning Retention Ratio (%), as of Mar 25, the value is 91.18. This value exceeds the healthy maximum of 70. It has decreased from 94.70 (Mar 24) to 91.18, marking a decrease of 3.52.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.57. This value exceeds the healthy maximum of 70. It has decreased from 96.75 (Mar 24) to 93.57, marking a decrease of 3.18.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.63. This value is within the healthy range. It has increased from 6.64 (Mar 24) to 13.63, marking an increase of 6.99.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.70. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 7.70, marking an increase of 4.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,753.81. It has increased from 5,509.59 (Mar 24) to 8,753.81, marking an increase of 3,244.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 2.86 (Mar 24) to 3.43, marking an increase of 0.57.
- For EV / EBITDA (X), as of Mar 25, the value is 12.06. This value is within the healthy range. It has increased from 11.30 (Mar 24) to 12.06, marking an increase of 0.76.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
- For Retention Ratios (%), as of Mar 25, the value is 91.17. This value exceeds the healthy maximum of 70. It has decreased from 94.69 (Mar 24) to 91.17, marking a decrease of 3.52.
- For Price / BV (X), as of Mar 25, the value is 4.30. This value exceeds the healthy maximum of 3. It has increased from 3.63 (Mar 24) to 4.30, marking an increase of 0.67.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Epigral Ltd:
- Net Profit Margin: 13.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.3% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.78% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 11.4 (Industry average Stock P/E: 28.96)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.98%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | �Epigral Tower�, Behind Safal Profitaire, Ahmedabad Gujarat 380015 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Maulik Patel | Chairman & Managing Director |
| Mr. Kaushal Soparkar | Executive Director |
| Mr. Ankit Patel | Non Exe.Non Ind.Director |
| Mr. Karana Patel | Non Exe.Non Ind.Director |
| Mr. Darshan Patel | Non Exe.Non Ind.Director |
| Mr. Manubhai Patel | Independent Director |
| Mr. Sanjay Asher | Independent Director |
| Mr. Kanubhai Patel | Independent Director |
| Mr. Raju Swamy | Independent Director |
| Ms. Priyanka Chopra | Independent Woman Director |
FAQ
What is the intrinsic value of Epigral Ltd?
Epigral Ltd's intrinsic value (as of 27 January 2026) is ₹1084.68 which is 1.75% higher the current market price of ₹1,066.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹4,597 Cr. market cap, FY2025-2026 high/low of ₹2,114/1,056, reserves of ₹2,057 Cr, and liabilities of ₹3,235 Cr.
What is the Market Cap of Epigral Ltd?
The Market Cap of Epigral Ltd is 4,597 Cr..
What is the current Stock Price of Epigral Ltd as on 27 January 2026?
The current stock price of Epigral Ltd as on 27 January 2026 is ₹1,066.
What is the High / Low of Epigral Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Epigral Ltd stocks is ₹2,114/1,056.
What is the Stock P/E of Epigral Ltd?
The Stock P/E of Epigral Ltd is 11.4.
What is the Book Value of Epigral Ltd?
The Book Value of Epigral Ltd is 487.
What is the Dividend Yield of Epigral Ltd?
The Dividend Yield of Epigral Ltd is 0.56 %.
What is the ROCE of Epigral Ltd?
The ROCE of Epigral Ltd is 24.9 %.
What is the ROE of Epigral Ltd?
The ROE of Epigral Ltd is 22.3 %.
What is the Face Value of Epigral Ltd?
The Face Value of Epigral Ltd is 10.0.